ACADIA Pharmaceuticals(us:ACAD)

    17.16

    +1.72%

    Updated on 2024-12-23

    Open:16.86
    Close:17.16
    High:17.19
    Low:16.62
    Pre Close:16.87
    Volume:529357.00
    Amount:8.97M
    Turnover:0.32%
    Shares:166.39M
    MarketCap:2.85B
    DateTotalTotal SharesTotal RatioNewIncreasedDecreased
    2024-06-3029616072675196.91%37110115
    2024-03-3131615967216896.79%48100131
    2023-12-3130215935377596.78%59102101
    2023-09-3026915491471894.48%399199
    2023-06-3026115757900796.46%3376107
    2023-03-3125415509104495.51%367495
    2022-12-3124615567131996.06%2973102
    2022-09-3026415025210592.82%2279114
    dateorgNametotalratiochangeShareschangeRatio
    2024-06-30Baker Bros. Advisors Lp4287791625.85%133040.03%
    2024-06-30Vanguard Group Inc137121318.27%4135903.11%
    2024-06-30Rtw Investments, Lp137075068.26%-121809-0.88%
    2024-06-30Blackrock Inc.120622137.27%3934733.37%
    2024-06-30State Street Corp58007903.50%-200613-3.34%
    2024-06-30Point72 Asset Management, L.P.37101402.24%2933440377.68%
    2024-06-30Millennium Management Llc29377141.77%83237039.54%
    2024-06-30D. E. Shaw & Co., Inc.29349261.77%29290611.09%
    2024-06-30Geode Capital Management, Llc28447141.72%514771.84%
    2024-06-30Marshall Wace, Llp27743531.67%2251940431.06%

    About

    ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
    Address:12830 El Camino Real,Suite 400

    Market Movers